Skip to main content
. 2023 Jan 12;12(1):183. doi: 10.3390/antiox12010183

Figure A1.

Figure A1

Analysis of ferroptosis in F-OVCAc. (A) Histogram of colony formation in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days measured by MTT assay in OVCA2; (B) Histogram of Malondialdehyde (MDA) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (C) Histogram of Iron (II) (Fe2+) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (D) Histogram of cell viability in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days measured by MTT assay in OVCA2; (E) Histogram of reactive oxygen species (ROS) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (F) Histogram of ratio GSH:GSSG in OVCAc treated with 500 nM of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (G) Histogram of colony formation in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (H) Histogram of Malondialdehyde (MDA) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (I) Histogram of Iron (II) (Fe2+) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (J) Histogram of cell viability in OVCAc treated with several concentrations (250 nM, 500 nM and 1µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 6 days measured by MTT assay in OVCA2; (K) Histogram of reactive oxygen species (ROS) levels in OVCAc treated with several concentrations (250 nM, 500 nM and 1 µM) of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 3 days in OVCA2; (L) Histogram of ratio GSH:GSSG in OVCAc treated with 500 nM of ferroptotic inducers ((1S,3R)-RSL3 (RSL3) and Erastin (Era)) for 6 days in OVCA2. The graphs show the mean ± SD of three independent experiments * p < 0.05 and ** p < 0.01. Related to Figure 2.